‘Otc Pharmaceutical Market Set To Grow To $183bn By 2022’ Says Visiongain Report

13 August 2018
Pharma

Visiongain has launched a new pharma report Anti- Global OTC Pharmaceutical Market Forecast 2017-2027: Cough, Cold and Allergy, Analgesics, Gastrointestinal, Dermatology, Eye Care, Smoking Cessation Aids, Others

The potential of the OTC pharmaceutical market remains significant and it is a growing segment in the largely stagnant overall pharmaceutical market. In the face of looming patent expiry and falling R&D productivity, the consumer healthcare and OTC business offers distinct advantages to pharmaceutical companies looking to create a diverse portfolio of businesses that achieves sustained revenue growth over the next ten years.

The lead analyst of the report commented “The growth of the OTC Pharmaceutical market will be driven by ageing demographic, cost pressures on healthcare providers, liberalisation of regulatory requirements, shifting cultural practices towards self-medication, and the continued switching of drugs from prescription-only to OTC.
Competition from private-label brands, regulatory concerns over OTC switching and the effective marketing of products via the Internet and social media are some of the challenges that OTC manufacturers and brands will need to address in the future.”

Leading companies featured in the report include Bayer AG, GlaxoSmithKline (GSK) Consumer Care, Perrigo Company PLC, Johnson & Johnson, Daiichi Sankyo Co., Ltd, Pfizer Inc., Procter & Gamble, Sanofi S.A, Reckitt Benckiser Group PLC, Cipla, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021

Read

Visiongain Publishes Aptamer Technologies Market Report 2021-2031

Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.

29 April 2021

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.

29 April 2021

Read

Visiongain Publishes Antiviral Drugs Treatment Market Report 2021-2031

Rising incidences of viral infection; increasing geriatric population is projected to propel the demand for anti-viral drugs; advancement in anti-viral drugs R&D is driving the market growth; and rising strategic initiatives for anti-viral drugs market is another major factor propelling the market growth worldwide are some of the major factors that propel the global antiviral drugs treatment market growth.

28 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever